Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Encompass Health Corp has a consensus price target of $99.89 based on the ratings of 18 analysts. The high is $135 issued by Stephens & Co. on June 5, 2025. The low is $57 issued by Barclays on March 14, 2023. The 3 most-recent analyst ratings were released by Stephens & Co., Keybanc, and UBS on June 5, 2025, May 27, 2025, and April 28, 2025, respectively. With an average price target of $133.33 between Stephens & Co., Keybanc, and UBS, there's an implied 11.49% upside for Encompass Health Corp from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/05/2025 | Buy Now | 12.89% | Stephens & Co. | Raj Kumar | $135 → $135 | Reiterates | Overweight → Overweight | Get Alert |
05/27/2025 | Buy Now | 12.89% | Keybanc | Paul Knight | $122 → $135 | Maintains | Overweight | Get Alert |
04/28/2025 | Buy Now | 8.7% | UBS | Andrew Mok | $117 → $130 | Maintains | Buy | Get Alert |
04/28/2025 | Buy Now | 4.52% | RBC Capital | Ben Hendrix | $110 → $125 | Maintains | Outperform | Get Alert |
04/28/2025 | Buy Now | 12.89% | Truist Securities | David Macdonald | $116 → $135 | Reiterates | Buy → Buy | Get Alert |
04/25/2025 | Buy Now | 2.02% | Keybanc | Matthew Gillmor | $120 → $122 | Maintains | Overweight | Get Alert |
04/25/2025 | Buy Now | 7.87% | Barclays | Andrew Mok | $118 → $129 | Maintains | Overweight | Get Alert |
02/11/2025 | Buy Now | -8.02% | RBC Capital | Ben Hendrix | $110 → $110 | Reiterates | Outperform → Outperform | Get Alert |
02/10/2025 | Buy Now | 0.34% | Keybanc | Matthew Gillmor | $117 → $120 | Maintains | Overweight | Get Alert |
02/07/2025 | Buy Now | -1.33% | Barclays | Andrew Mok | $116 → $118 | Maintains | Overweight | Get Alert |
10/30/2024 | Buy Now | -8.02% | RBC Capital | Ben Hendrix | $105 → $110 | Maintains | Outperform | Get Alert |
10/30/2024 | Buy Now | -3% | Truist Securities | David Macdonald | $108 → $116 | Reiterates | Buy → Buy | Get Alert |
10/29/2024 | Buy Now | -3% | Barclays | Andrew Mok | $109 → $116 | Maintains | Overweight | Get Alert |
10/29/2024 | Buy Now | -2.17% | Keybanc | Matthew Gillmor | $115 → $117 | Maintains | Overweight | Get Alert |
10/14/2024 | Buy Now | -9.69% | Truist Securities | David Macdonald | $104 → $108 | Maintains | Buy | Get Alert |
10/11/2024 | Buy Now | -3.84% | Keybanc | Matthew Gillmor | → $115 | Initiates | → Overweight | Get Alert |
09/26/2024 | Buy Now | -12.2% | RBC Capital | Ben Hendrix | $95 → $105 | Maintains | Outperform | Get Alert |
09/25/2024 | Buy Now | -8.02% | UBS | Andrew Mok | $100 → $110 | Maintains | Buy | Get Alert |
08/15/2024 | Buy Now | -13.04% | Truist Securities | David Macdonald | $100 → $104 | Maintains | Buy | Get Alert |
08/08/2024 | Buy Now | -16.38% | UBS | Andrew Mok | $96 → $100 | Maintains | Buy | Get Alert |
08/06/2024 | Buy Now | -12.2% | Stephens & Co. | Scott Fidel | $105 → $105 | Reiterates | Overweight → Overweight | Get Alert |
08/06/2024 | Buy Now | -8.86% | Barclays | Andrew Mok | $113 → $109 | Maintains | Overweight | Get Alert |
07/15/2024 | Buy Now | -16.38% | Truist Securities | David Macdonald | $95 → $100 | Maintains | Buy | Get Alert |
07/10/2024 | Buy Now | -5.51% | Barclays | Andrew Mok | $108 → $113 | Maintains | Overweight | Get Alert |
07/10/2024 | Buy Now | -16.38% | Leerink Partners | Whit Mayo | → $100 | Initiates | → Outperform | Get Alert |
06/05/2024 | Buy Now | -21.4% | Stephens & Co. | Scott Fidel | $94 → $94 | Reiterates | Overweight → Overweight | Get Alert |
05/22/2024 | Buy Now | -20.56% | RBC Capital | Ben Hendrix | $83 → $95 | Maintains | Outperform | Get Alert |
04/26/2024 | Buy Now | -20.56% | Raymond James | John Ransom | $85 → $95 | Reiterates | Strong Buy → Strong Buy | Get Alert |
04/25/2024 | Buy Now | -9.69% | Barclays | Andrew Mok | $101 → $108 | Maintains | Overweight | Get Alert |
04/25/2024 | Buy Now | -20.56% | Mizuho | Ann Hynes | $93 → $95 | Maintains | Buy | Get Alert |
03/28/2024 | Buy Now | -15.54% | Barclays | Andrew Mok | $95 → $101 | Maintains | Overweight | Get Alert |
03/06/2024 | Buy Now | -20.56% | Barclays | Andrew Mok | → $95 | Initiates | → Overweight | Get Alert |
02/09/2024 | Buy Now | -30.6% | RBC Capital | Ben Hendrix | $83 → $83 | Reiterates | Outperform → Outperform | Get Alert |
02/09/2024 | Buy Now | -28.09% | Truist Securities | David Macdonald | $82 → $86 | Maintains | Buy | Get Alert |
02/09/2024 | Buy Now | -31.43% | Mizuho | Ann Hynes | $77 → $82 | Maintains | Buy | Get Alert |
01/16/2024 | Buy Now | -28.92% | Stephens & Co. | Scott Fidel | $85 → $85 | Reiterates | Overweight → Overweight | Get Alert |
09/28/2023 | Buy Now | -30.6% | RBC Capital | Ben Hendrix | → $83 | Reiterates | Outperform → Outperform | Get Alert |
08/08/2023 | Buy Now | -30.6% | RBC Capital | Ben Hendrix | $70 → $83 | Maintains | Outperform | Get Alert |
08/04/2023 | Buy Now | -41.47% | Barclays | Jason Goldberg | $61 → $70 | Maintains | Equal-Weight | Get Alert |
08/04/2023 | Buy Now | -33.1% | Credit Suisse | Jonathan Yong | $76 → $80 | Maintains | Outperform | Get Alert |
08/03/2023 | Buy Now | -28.92% | Raymond James | John Ransom | $80 → $85 | Maintains | Strong Buy | Get Alert |
08/03/2023 | Buy Now | -31.43% | Truist Securities | David Macdonald | $75 → $82 | Maintains | Buy | Get Alert |
08/03/2023 | Buy Now | -35.61% | Mizuho | Ann Hynes | $74 → $77 | Maintains | Buy | Get Alert |
08/03/2023 | Buy Now | -40.63% | Barclays | Jason Goldberg | $61 → $71 | Maintains | Equal-Weight | Get Alert |
07/20/2023 | Buy Now | -34.78% | Stephens & Co. | Scott Fidel | → $78 | Reiterates | Overweight → Overweight | Get Alert |
06/29/2023 | Buy Now | -34.78% | Stephens & Co. | Scott Fidel | $74 → $78 | Maintains | Overweight | Get Alert |
05/02/2023 | Buy Now | -41.47% | RBC Capital | Ben Hendrix | $66 → $70 | Maintains | Outperform | Get Alert |
05/02/2023 | Buy Now | -33.1% | Raymond James | John Ransom | $72 → $80 | Maintains | Strong Buy | Get Alert |
05/01/2023 | Buy Now | -38.96% | Deutsche Bank | Pito Chickering | $70 → $73 | Maintains | Buy | Get Alert |
05/01/2023 | Buy Now | -38.12% | Stephens & Co. | Scott Fidel | $70 → $74 | Maintains | Overweight | Get Alert |
05/01/2023 | Buy Now | -36.45% | Credit Suisse | Jonathan Yong | $73 → $76 | Maintains | Outperform | Get Alert |
05/01/2023 | Buy Now | -38.12% | Mizuho | Ann Hynes | $69 → $74 | Maintains | Buy | Get Alert |
04/28/2023 | Buy Now | -38.12% | B of A Securities | Kevin Fischbeck | $69 → $74 | Maintains | Buy | Get Alert |
04/04/2023 | Buy Now | -48.99% | Barclays | Jason Goldberg | $57 → $61 | Maintains | Equal-Weight | Get Alert |
03/14/2023 | Buy Now | -52.34% | Barclays | Steve Valiquette | → $57 | Initiates | → Equal-Weight | Get Alert |
02/09/2023 | Buy Now | -37.29% | Truist Securities | David Macdonald | $70 → $75 | Maintains | Buy | Get Alert |
02/09/2023 | Buy Now | -38.96% | Credit Suisse | A.J. Rice | $62 → $73 | Maintains | Outperform | Get Alert |
02/09/2023 | Buy Now | -42.3% | Mizuho | Ann Hynes | $65 → $69 | Maintains | Buy | Get Alert |
02/08/2023 | Buy Now | -41.47% | Stephens & Co. | Scott Fidel | → $70 | Maintains | Overweight | Get Alert |
10/28/2022 | Buy Now | -51.5% | Stephens & Co. | Scott Fidel | $60 → $58 | Maintains | Overweight | Get Alert |
10/28/2022 | Buy Now | -39.79% | Raymond James | John Ransom | $65 → $72 | Maintains | Strong Buy | Get Alert |
09/21/2022 | Buy Now | -48.16% | Credit Suisse | A.J. Rice | $63 → $62 | Maintains | Outperform | Get Alert |
08/24/2022 | Buy Now | -44.81% | RBC Capital | Ben Hendrix | $82 → $66 | Maintains | Outperform | Get Alert |
08/08/2022 | Buy Now | -45.65% | Truist Securities | David Macdonald | $75 → $65 | Maintains | Buy | Get Alert |
08/04/2022 | Buy Now | -45.65% | BMO Capital | Matt Borsch | $83 → $65 | Maintains | Outperform | Get Alert |
08/04/2022 | Buy Now | -45.65% | Raymond James | John Ransom | $70 → $65 | Maintains | Strong Buy | Get Alert |
08/04/2022 | Buy Now | -47.32% | Barclays | Steve Valiquette | $80 → $63 | Maintains | Overweight | Get Alert |
The latest price target for Encompass Health (NYSE:EHC) was reported by Stephens & Co. on June 5, 2025. The analyst firm set a price target for $135.00 expecting EHC to rise to within 12 months (a possible 12.89% upside). 23 analyst firms have reported ratings in the last year.
The latest analyst rating for Encompass Health (NYSE:EHC) was provided by Stephens & Co., and Encompass Health reiterated their overweight rating.
There is no last upgrade for Encompass Health
There is no last downgrade for Encompass Health.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Encompass Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Encompass Health was filed on June 5, 2025 so you should expect the next rating to be made available sometime around June 5, 2026.
While ratings are subjective and will change, the latest Encompass Health (EHC) rating was a reiterated with a price target of $135.00 to $135.00. The current price Encompass Health (EHC) is trading at is $119.59, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.